Filing Flows

Filing Flows › Companies › Nuvation Bio › Timeline

Nuvation Bio stock timeline

A year of the price with every insider trade, planned sale, earnings report and material 8-K marked

252 sessions−17.1% to $4.16

Nuvation Bio (NUVB) stock fell 17% over the last 252 sessions, to $4.16. On the way it reported 4 quarters, its insiders filed 9 open-market trades and 4 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.

NUVB: a year of the stock with every disclosure on itNUVB: a year of the stock with every disclosure on it$5.20$6.80$8.39$9.98▼2025-11-17 · Liu Dongfang sold $72K▼2025-11-19 · Hanley David C. sold $1.4M▼2025-11-19 · Liu Dongfang sold $76K▼2025-11-20 · Hattersley Gary sold $2.7M▼2025-11-20 · Liu Dongfang sold $140K▼2025-11-25 · Liu Dongfang sold $75K▼2025-11-26 · Liu Dongfang sold $80K▼2025-12-01 · Liu Dongfang sold $1.2M◆2026-01-12 · Material definitive agreement●2026-03-02 · Earnings: missed the EPS estimate by -91.1%●2026-05-04 · Earnings: missed the EPS estimate by -23.6%▲2026-06-09 · Mashal Robert bought $118K▽2026-06-23 · Form 144: Stacy Markel plans to sell $720K▽2026-06-23 · Form 144: Kerry Wentworth plans to sell $363K▽2026-06-23 · Form 144: Philippe Sauvage plans to sell $275K◆2026-06-30 · Material definitive agreement◆2026-07-06 · New debt or off-balance-sheet obligation●2026-08-06 · Earnings: missed the EPS estimate by -25.1%▽2026-08-19 · Form 144: Gary Hattersley plans to sell $696K●2026-11-04 · Earnings: beat the EPS estimate by 12.4%▼Insider sale◆8-K event●Earnings report▲Insider buy▽Planned sale (Form 144)2025-11-062026-11-06
Daily closes, Nov 6, 2025 to Nov 6, 2026; hover a mark for the filing.

Each mark, and what followed

DateKindWhatNext session5 sessions21 sessions
Nov 4, 2026EarningsEarnings: beat the EPS estimate by 12.4%+0.8% (−0.8% vs SPY)——
Aug 19, 2026Form 144Form 144: Gary Hattersley plans to sell $696K+4.2% (+4.0% vs SPY)+2.0% (+2.2% vs SPY)−13.7% (−13.1% vs SPY)
Aug 6, 2026EarningsEarnings: missed the EPS estimate by -25.1%−4.2% (−4.0% vs SPY)+0.8% (+0.4% vs SPY)+6.1% (+5.6% vs SPY)
Jul 6, 20268-KNew debt or off-balance-sheet obligation+1.2% (+1.7% vs SPY)+3.0% (+3.3% vs SPY)+14.0% (+11.4% vs SPY)
Jun 30, 20268-KMaterial definitive agreement−4.7% (−4.6% vs SPY)+3.3% (+3.5% vs SPY)+16.5% (+17.2% vs SPY)
Jun 23, 2026Form 144Form 144: Philippe Sauvage plans to sell $275K+4.7% (+6.2% vs SPY)−2.6% (−2.2% vs SPY)+12.9% (+12.5% vs SPY)
Jun 23, 2026Form 144Form 144: Kerry Wentworth plans to sell $363K+4.7% (+6.2% vs SPY)−2.6% (−2.2% vs SPY)+12.9% (+12.5% vs SPY)
Jun 23, 2026Form 144Form 144: Stacy Markel plans to sell $720K+4.7% (+6.2% vs SPY)−2.6% (−2.2% vs SPY)+12.9% (+12.5% vs SPY)
Jun 9, 2026Insider buyMashal Robert bought $118K+2.7% (+3.0% vs SPY)+6.8% (+4.7% vs SPY)+24.1% (+22.2% vs SPY)
May 4, 2026EarningsEarnings: missed the EPS estimate by -23.6%−1.8% (−1.4% vs SPY)+6.5% (+4.1% vs SPY)+8.7% (+3.5% vs SPY)
Mar 2, 2026EarningsEarnings: missed the EPS estimate by -91.1%−1.2% (−1.2% vs SPY)−25.3% (−23.3% vs SPY)−37.8% (−29.9% vs SPY)
Jan 12, 20268-KMaterial definitive agreement−21.9% (−22.0% vs SPY)−31.8% (−31.5% vs SPY)−34.2% (−34.0% vs SPY)
Dec 1, 2025Insider saleLiu Dongfang sold $1.2M−1.9% (−1.4% vs SPY)+6.3% (+5.9% vs SPY)+10.7% (+9.9% vs SPY)
Nov 26, 2025Insider saleLiu Dongfang sold $80K+1.6% (+1.0% vs SPY)+6.0% (+4.7% vs SPY)+17.6% (+15.1% vs SPY)
Nov 25, 2025Insider saleLiu Dongfang sold $75K+6.2% (+5.2% vs SPY)+0.8% (−1.1% vs SPY)+25.1% (+21.6% vs SPY)
Nov 20, 2025Insider saleLiu Dongfang sold $140K−2.0% (−0.4% vs SPY)+11.4% (+8.8% vs SPY)+27.8% (+24.8% vs SPY)
Nov 20, 2025Insider saleHattersley Gary sold $2.7M−2.0% (−0.4% vs SPY)+11.4% (+8.8% vs SPY)+27.8% (+24.8% vs SPY)
Nov 19, 2025Insider saleLiu Dongfang sold $76K+39.9% (+39.5% vs SPY)+49.6% (+47.3% vs SPY)+62.8% (+60.3% vs SPY)
Nov 19, 2025Insider saleHanley David C. sold $1.4M+39.9% (+39.5% vs SPY)+49.6% (+47.3% vs SPY)+62.8% (+60.3% vs SPY)
Nov 17, 2025Insider saleLiu Dongfang sold $72K−4.0% (−3.1% vs SPY)+36.3% (+38.3% vs SPY)+57.8% (+56.7% vs SPY)

Insiders’ record here

In the year on the chart, Nuvation Bio's insiders reported 1 open-market buy ($118K) and 8 sales ($5.7M). Of the 9 old enough to score, 8 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was +28.8% and after a sale −26.6%.

Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →

What this kind of 8-K usually did

Item8-KsNext session, medianUp next session21 sessions, medianTypical size
1.01 Material definitive agreement23,5250.0%51%+1.0%±1.4%
1.02 Termination of a material agreement2,3680.0%51%+1.1%±1.5%
2.03 New debt or off-balance-sheet obligation13,2680.0%50%+1.2%±1.3%

Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →

Report card: every quarter against the estimate → Nuvation Bio: every quarter → Live insider trades →

Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.